RM-1, a murine prostate cancer cell line, was chosen due to its compatibility with the C57BL/6 genetic background and its robust tumorigenicity, which enabled effective assessment of immune modulation upon TOPK deficiency. This evidence concerns the gene PBK and prostate carcinoma.